Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07498595 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a single-arm study designed to evaluate the safety and efficacy of TILs combined with third-generation EGFR-TKIs therapy for patients with EGFR-mutant NSCLC resistant to TKI.
Trial Details
NCT Number NCT07498595
Lead Sponsor Tianjin Medical University General Hospital
Conditions
(from sponsor)		 EGFR-TKI-resistant Non-Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov